Withdrawn
Tyrosine Kinase Inhibitors for renal cell carcinoma (RCC)
4 January 2022
Published on 02 Jul 2018
Last Updated on 04 Jan 2022
Tyrosine Kinase Inhibitors (pazopanib and sunitinib) for the first-line treatment of advanced and/or metastatic renal cell carcinoma Guidance is outdated and has been withdrawn on 4 Jan 2022.
Please refer to the updated recommendations on Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors and Everolimus for treating advanced renal cell cancer here.
Tyrosine kinase inhibitors for RCC (Withdrawn 4 Jan 2022) [PDF, 255 KB]